O-GlcNAc转移酶在肝细胞癌组织中的表达及其临床意义

doi:10.13481/j.1671-587x.20170523

吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (05): 980-984.doi: 10.13481/j.1671-587x.20170523

O-GlcNAc转移酶在肝细胞癌组织中的表达及其临床意义

崔银星¹, 孔菲², 赵旭², 高普均²

1. 吉林大学第一医院康复医学科, 吉林长春 130021;
2. 吉林大学第一医院肝胆胰内科, 吉林长春 130021

收稿日期:2017-04-18 出版日期:2017-09-28 发布日期:2017-09-29
通讯作者: 高普均,教授,博士研究生导师(Tel:0431-84808105,E-mail:gpj0411@163.com) E-mail:gpj0411@163.com
作者简介:崔银星(1986-),女,吉林省延吉市人,医师,医学硕士,主要从事内科系统康复方面的研究。
基金资助:
韩国国家科研基金基础科学研究计划资助课题（2011-0027071）；吉林大学第一医院青年基金资助课题（JDYY72016012）

Expression of O-GlcNAc transferase in hepatocellular carcinoma tissue and its clinical significance

CUI Yinxing¹, KONG Fei², ZHAO Xu², GAO Pujun²

1. Department of Rehabilitation, First Hospital, Jilin University, Changchun 130021, China;
2. Department of Hepatobiliary, First Hospital, Jilin University, Changchun 130021, China

Received:2017-04-18 Online:2017-09-28 Published:2017-09-29

摘要/Abstract

摘要： 目的：探讨氧连氮-乙酰葡萄糖胺转移酶（OGT）在原发性肝细胞癌（HCC）组织、细胞及血清中表达情况，阐明OGT在HCC的诊断和治疗中的意义。方法：采用Western blotting法分别检测20例HCC组织和癌旁组织中以及8例肝癌细胞株和正常人肝细胞裂解物中OGT蛋白表达水平，采用直接酶联免疫吸附测定法（ELISA）检测20名健康志愿者、肝硬化（LC）、HCC患者血清中OGT蛋白表达水平，分析HCC组织、细胞、血清中OGT蛋白表达水平与肿瘤发生发展的关系。结果：Western blotting检测，OGT在HCC肿瘤组织及相对应癌旁组织中均有表达，HCC患者肿瘤组织中OGT阳性表达率高于相对应癌旁组织（P < 0.05）；同时OGT在肝细胞癌株及正常人肝细胞裂解物中均有表达，而肝细胞癌株中阳性表达率高于正常人肝细胞裂解物（P < 0.05）。ELISA法检测，HCC和LC患者血清中OGT表达水平均高于健康志愿者（P < 0.05）。结论：OGT在HCC肿瘤组织中表达升高，OGT有望成为HCC新的诊断靶点。

关键词: 酶联免疫吸附测定法, 肝细胞癌, 氧连氮-乙酰葡萄糖胺, 氧连氮-乙酰葡萄糖胺转移酶, 蛋白免疫印迹法

Abstract: Objective: To investigate the expressions of O-GlcNAc transferase (OGT) in the hepatocellular carcinoma (HCC) tissue, cells and serum, and to clarify the significance of OGT in diagnosis and treatment of HCC. Methods: Western blotting method was used to detect the expression levels of OGT in 20 samples of HCC tissue and matched non-tumor tissue, 8 hepatoma cell lines and normal liver (human) cell lysate. The expression levels of serum OGT were detected by direct ELISA in 20 liver cirrhosis (LC) patients, 20 HCC patients and 20 healthy volunteers.The relationship between the expression levels of protein in HCC tissue,cells and serum and the occurrence and development of tumor were analyzed. Results: The Western blotting results showed there were expressions of OGT in both HCC tissue and matched non-tumor tissue; The positive expression rate of OGT in HCC tissue was significantly higher than that in non-tumor tissue (P<0.05).There were expressions of OGT in both hepatoma cell lines and normal liver (human) cell lysate; the positive expression rate of OGT in HCC cell lysate was significantly higher than that in the normal liver cell lysate(P<0.05).The result of direct ELISA showed that the serum OGT levels of the LC and HCC patients were equally higher than that of the healthy volunteers (P<0.05). Conclusion: OGT highly expresses in HCC tissue and OGT is a promising biomarker for the diagnosis of HCC.

Key words: Western blotting method, O-linked β-N-acetylglucosamine, O-linked β-N-acetylglucosamine transferase, hepatocellular carcinoma, enzyme-linked immunosorbent assay

中图分类号:

R575

崔银星, 孔菲, 赵旭, 高普均. O-GlcNAc转移酶在肝细胞癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2017, 43(05): 980-984.

CUI Yinxing, KONG Fei, ZHAO Xu, GAO Pujun. Expression of O-GlcNAc transferase in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 980-984.

参考文献

[1] Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005[J].CA Cancer J Clin, 2005,55(1):10-30.
[2] 刘会春.中国原发性肝癌治疗指南解读[J].肝胆外科杂志, 2013, 21(1):12-14.
[3] Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins:signal transduction and O-GlcNAc[J].Science, 2001, 291(5512):2376-2378.
[4] Iyer SP, Hart GW. Roles of the tetratricopeptide repeat domain in O-GlcNAc transferase targeting and protein substrate specificity[J].J Biol Chem, 2003, 278(27):24608-24616.
[5] Haltiwanger RS, Blomberg MA, Hart GW. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a ur-idine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylgluco-saminyltransferase[J].J Biol Chem, 1992, 267(13):9005-9013.
[6] Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats[J].J Biol Chem, 1997, 272(14):9308-9315.
[7] Vaidyanathan K, Durning S, Wells L. Functional O-GlcNAc modifications:implications in molecular regulation and pathophysiology[J]. Crit Rev Biochem Mol Biol,2014,49(2):140-163.
[8] Huang X, Pan Q, Sun D, et al. O-GlcNAcylation of cofilin promotes breast cancer cell invasion[J]. J Biol Chem, 2013,288(51):36418-36425.
[9] Yehezkel G, Cohen L, Kliger A, et al. O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-β-D-glucosaminidase silencing on cell phenotype and transcriptome[J]. J Biol Chem, 2012, 287(34):28755-28769.
[10] Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells[J].J Biol Chem, 2013, 288(21):15121-15130.
[11] Starska K, Forma E, Brzezińska-Blaszczyk E,et al. Gene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancer[J]. Clin Exp Med,2015,15(4):455-468.
[12] Xu W, Zhang X, Wu JL,et al.O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stres[J].J Hepatol,2017, doi:10.1016/j.jhep.
[13] Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers,2016,2:16018.
[14] Ang C, Miura JT, Gamblin TC,et al. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options[J].J Surg Oncol,2016,113(1):55-61.
[15] Hong SW, Hur W, Choi JE, et al. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation[J]. Oncotarget, 2016,7(17):23482-23497.
[16] Byam J, Renz J, Millis JM. Liver transplantation for hepatocellularcarcinoma[J].Hepatobiliary Surg Nutr, 2013,2(1):22-30.
[17] Sohn KC, Lee KY, Park JE,et al. OGT functions as a catalytic chaperone under heat stress response:a unique defense role of OGT in hyperthermia[J]. Biochem Biophys Res Commun, 2004,322(3):1045-1051.
[18] Zhu Q, Zhou L, Yang Z, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation[J]. Med Oncol, 2012, 29(2):985-993.
[19] Starzl TE, Marchioro TL, Vonkaulla KN,et al. Homotransplantation of the liver in humans[J]. Surg Gynecol Obstet,1963, 117:659-676.
[20] Carr BI. Hepatocellular carcinoma:current management and future trends[J]. Gastroenterology, 2004, 127(5 Suppl 1):S218-224.
[21] 沈芝南,卢军华.肝细胞癌相关分子靶向治疗研究进展[J]. 临床肝胆病杂志,2015,31(1):130-134.
[22] 杨霄霄,马红.肝细胞癌肿瘤标志物的研究进展[J]. 临床肝胆病杂志,2016,32(4):811-815.
[23] 刘佳,朱琴梅,胡弘毅,等.Hedgehog信号在肝细胞癌发生发展中的作用[J]. 临床肝胆病杂志,2015,31(2):300-304.

O-GlcNAc转移酶在肝细胞癌组织中的表达及其临床意义

Expression of O-GlcNAc transferase in hepatocellular carcinoma tissue and its clinical significance

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

Metrics

本文评价

推荐阅读 0

[1]	历春, 关新刚, 王英楠, 徐聪睿, 盖晓东. Tum-5基因对肝细胞癌生长的抑制作用和对血管生成的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 58-62.
[2]	齐亚灵，赵文杰，方艳秋，陈玉强，孟德欣，王伟群，李尧，李文 . Survivin-ASODN对肝癌SMMC-7721细胞凋亡的促进作用及其机制[J]. 吉林大学学报(医学版), 2014, 40(04): 757-762.
[3]	蒋娟，黄学宽，曾志华，骆言，张超男，万磊，王玲. 电针对非酒精性脂肪肝大鼠血清RBP4水平的影响及其脂质调节作用机制[J]. 吉林大学学报(医学版), 2014, 40(03): 602-606.
[4]	张毅，张君薇，谢淑丽，王广义. RNAi沉默STAT3基因联合mTOR抑制剂rapamycin诱导BEL-7402肝癌细胞凋亡[J]. 吉林大学学报(医学版), 2013, 39(5): 903-908.
[5]	段秀梅\|邹亚斌\|马洪喜\|李树蕾\|王银萍\|王超\|李玉琴. 结核杆菌热休克蛋白70刺激表位在融合基因疫苗中的佐剂作用[J]. J4, 2012, 38(3): 506-511.
[6]	付京\|陈域\|雷团结\|李惠民\|雷海路\|邢建桥\|杜锡林. 射频消融与手术切除治疗老年性小肝细胞癌的疗效比较[J]. J4, 2011, 37(4): 733-737.
[7]	丁军, 刘桂峰, 修殿辉, 程凯亮, 赵金山. 葡聚糖超顺磁性氧化铁纳米颗粒在检测小鼠肝癌病灶中的应用及效果评价[J]. J4, 2010, 36(6): 1167-1170.
[8]	孙亚欣，张志超，贾明库. CD40与ICAM-1在原发性肝细胞癌组织中的表达及临床意义[J]. J4, 2009, 35(2): 348-351.
[9]	郭宏华，王江滨，孙文伟，李岩，张建中. 生长抑素受体亚型SSTR2和SSTR5 mRNA在肝癌组织中的表达及其临床意义[J]. J4, 2009, 35(1): 154-158.
[10]	李玉琴，谭岩，李树蕾，刘力华，段秀梅，方艳秋，许淑芬. 构建人肝细胞癌相关抗原HCA661和mtHSP70刺激表位的融合基因疫苗[J]. J4, 2007, 33(2): 373-376.